Clearmind Medicine Inc.

CMND

CA1850535016

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 01:32:03 2026-01-13 pm EST			5-day change	1st Jan Change
2.290 ^USD	+6.02%		-15.99%	+24.86%

Dec. 31	Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule	MT
Dec. 16	Clearmind Medicine announces successful completion of second cohort enrollment	RE

Clearmind Medicine Inc files for offering of up to 16 million common shares - SEC filing

Published on 12/03/2025 at 08:04 am EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Clearmind Medicine Inc.

Dec. 31	Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule	MT
Dec. 16	Clearmind Medicine announces successful completion of second cohort enrollment	RE
Dec. 16	Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100	CI
Dec. 12	Clearmind Medicine Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement	MT
Dec. 03	Clearmind Medicine Inc files for offering of up to 16 million common shares - SEC filing	RE
Dec. 02	Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder	CI
Dec. 02	Clearmind Medicine advances CMND-100 to dosing phase at Hadassah Medical Center	RE
Dec. 01	Clearmind advances alcoholism treatment with positive data, DSMB approval, and new trial site	RE
Dec. 01	Clearmind Medicine Inc. Announces Three Transformative Milestones in its FDA- Approved Phase I/IIa Clinical Trial for CMND-100	CI
Nov. 25	Clearmind Medicine Kicks-Off Patient Enrollment At Tel Aviv Sourasky Medical Center, Adding Another Site Activated in Its in Phase I/IIa Alcohol Use Disorder Trial	CI
Nov. 24	Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/Iia Clinical Trial for Cmnd-100 Following Positive Interim Safety Review	CI
Nov. 20	Neurothera Labs Inc. Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression	CI
Nov. 20	Clearmind Medicine Accelerate Fda-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site	CI
Nov. 18	Clearmind Medicine announces positive top-line results from first cohort of its FDA-approved Phase I/IIa clinical trial for alcohol use disorder	RE
Nov. 18	Clearmind Medicine Announces Positive Top-Line Results from First Cohort of Its Fda-Approved Phase I/Iia Clinical Trial for Alcohol Use Disorder	CI
Nov. 17	Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression	CI
Nov. 13	Clearmind Medicine Gets Final Approval for Psychedelic-Based Alcohol Use Disorder Trial in Israel	MT
Nov. 13	Clearmind Medicine Inc. Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center	CI
Nov. 12	Clearmind Medicine Inc. Announces Notice of Patent Publication for Depression Treatment	CI
Nov. 10	Clearmind Medicine Inc. Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder	CI
Nov. 05	Clearmind Medicine Inc. Expands Global Ip Protection for Meai in Depression Treatment with New South Korea Patent Filing	CI
25-10-31	Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy	CI
25-10-30	Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder	CI
25-10-27	Clearmind Medicine Inc Appoints Mary-Elizabeth Gifford as Chief of Global Impact	CI
25-10-21	Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder	CI

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Companyâs intellectual portfolio consists of 15 patent families, including 27 granted patents and 24 pending applications. The portfolio spans a range of jurisdictions, including the United States, Europe, India, and China.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 02 - Q4 2025 Earnings Release (Projected)

More about the company